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Abstract. A multiple dose, parallel group study was conducted to assess for a drug-drug interaction between the
pyronaridine/artesunate (PA) combination antimalarial and ritonavir. Thirty-four healthy adults were randomized (1:1)
to receive PA for 3 days or PA with ritonavir (100 mg twice daily for 17 days, PA administered on Days 8–10).
Pharmacokinetic parameters for pyronaridine, artesunate, and its active metabolite dihydroartemisinin (DHA) were
obtained after the last PA dose and for ritonavir on Days 1 and 10. Ritonavir coadministration did not markedly change
pyronaridine pharmacokinetics but resulted in a 27% increase in artesunate area under the curve (AUC) and a 38%
decrease in DHA AUC. Ritonavir exposure was increased 3.2-fold in the presence of PA. The only relevant safety
observations were increases in liver enzymes, only reaching a clinically significant grade in the PA + ritonavir arm. It was
concluded that coadministered ritonavir and PA interact to alter exposure to artesunate, DHA, and ritonavir itself.
INTRODUCTION
Artemisinin-based combination therapies (ACTs) are cen-
tral to the treatment of acute malaria infection. The ACTs
combine artemisinin derivatives, which produce rapid and
profound reductions in parasitemia, with longer acting part-
ner drugs capable of eliminating residual parasitemia. The
novel ACT Pyramax (PA), a fixed-dose combination of the
artemisinin derivative artesunate and the Mannich base deriv-
ative pyronaridine tetraphosphate, has been tested in Phase III
clinical trials as a 3-day, once daily treatment regimen for adult
and pediatric patients with acute uncomplicated falciparum or
vivax malaria.
The intent of this study (clinicaltrials.gov ID: NCT01156389)
was to assess the pharmacokinetic and safety implications
of coadministration of PA and ritonavir, a protease inhibitor
commonly used as a pharmacokinetic booster in antiretroviral
drug regimens. Ritonavir was selected for study both because
of the high prevalence of human immunodeficiency virus
(HIV) in malaria-endemic regions, and the substantial over-
lap between the pharmacokinetic pathways affected by ritona-
vir administration and the pathways involved in metabolism of
pyronaridine and dihydroartemisinin (DHA), the active metab-
olite of artesunate. Specifically, ritonavir is both an inhibitor
and substrate of CYP3A4, CYP2D6, and the drug efflux pump,
P-glycoprotein (P-gp).
1–4 Additionally, ritonavir has the capac-
ity for inducing expression of CYP3A4, CYP1A2, and UDP-
glucuronosyltransferases (UGTs).
4 Because CYP3A4, CYP2D6,
and CYP1A2 are considered likely responsible for pyronaridine
metabolism, and UGTs are known to be responsible for DHA
metabolism,
5 pharmacokinetic and safety outcomes associated
with coadministration of ritonavir, dosed as a pharmacokinetic
enhancer,
1 and PA were judged to merit investigation.
MATERIALS AND METHODS
Study design. Medically normal male and female adults, 18
to 55 years of age, able to understand and comply with study
procedures were considered for inclusion. Exclusion criteria
were as follows: known history or evidence of any clinically
significant medical disorder, clinically significant abnor-
malities in biochemical, hematological, or urine test results,
known history of hypersensitivity or adverse reaction to any
study drug, HIV seropositivity, presence or recent history of
tobacco abuse (³ 10 cigarettes/day), required chronic use of
any prescription medication, or use of over-the-counter
medications, including vitamins, analgesics, or antacids, 1 week
before the study start. All subjects were required to have
normal serum alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and bilirubin. Inclusion of non-
pregnant female subjects of childbearing potential was contin-
gent on those subjects agreeing to appropriate contraceptive
methods. All subjects provided written informed consent
for their participation in the trial. This study was approved
before starting by the Ethics Committee of both Basel
and Swissmedic.
After enrollment, subjects were randomly assigned in a
1:1 ratio to Arm A or Arm B. Figure 1 provides a timeline of
study drug administration for each arm. Subjects in Arm A
were administered ritonavir soft gelatin capsules (Norvir; Lot
no.: 6008303; Abbott Laboratories, Abbott Park, IL) 100 mg
once on Day 1, followed by ritonavir 100 mg every 12 hours
on Days 2–17; these subjects were additionally administered
three or four PA tablets, depending on weight, once daily on
Days 8, 9, and 10. Subjects weighing < 65 kg were adminis-
tered three PA tablets (180 mg pyronaridine tetraphosphate:
60 mg artesunate per tablet) per day; subjects weighing 65 kg
or more were administered four tablets per day. Subjects in
Arm A were residents in the clinical research unit starting the
evening before the first administration of ritonavir on the
morning of Day 1 through the last administration of ritonavir
on Day 17; these subjects returned for ambulatory clinic visits
on Days 22, 29, 36, 43, and 50. Subjects in Arm B were admin-
istered three or four PA tablets, depending on weight, on
Days 1, 2, and 3. Subjects in Arm B were residents from the
evening before the first administration of PA on Day 1
through the morning of Day 4; these subjects returned for
ambulatory clinic visits on Days 5, 6, 8, 15, 22, 29, 36, and 43.
In both Arm A and Arm B, morning doses of the study drug
were administered with 240 mL of mineral water following
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489an overnight fast. In Arm A, the evening dose of ritonavir
was similarly administered with 240 mL of mineral water.
Intake of grapefruit, grapefruit juice, alcoholic beverages, or
caffeine-containing food or beverages within 48 hours before
study drug administration was not allowed. Additionally, no
medications apart from the study drugs and agents to ameliorate
adverse effects were allowed during the course of the study.
Acetaminophen and aspirin were to be avoided during the study.
Pharmacokinetic sampling. In Arm A, plasma samples for
analysis of ritonavir concentrations were collected on Days 1
and 10 at pre-dose and 1, 2, 3, 4, 6, 8, 9, 12, 18, and 24 hours
post-dose. Plasma samples for artesunate/DHA analysis were
collected on Day 10 at pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6,
8, and 12 hours post-dose. Blood samples for pyronaridine
analysis were collected on Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3,
4, 6, 8, 12, and 24 hours after the last dose and at 2, 3, 5, 12, 19,
26, 33, and 40 days after the last dose. In addition, trough
concentrations for all analytes were assessed on study Day 8
(pre-dose for pyronaridine and artesunate/DHA) and Day 9
before the morning dosing.
In Arm B, plasma samples for artesunate/DHA analysis
were collected on Day 3 at pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2,
3, 4, 6, 8, and 12 hours post-dose. Blood concentrations for
pyronaridine were collected on Day 3 at pre-dose, 0.5, 1, 1.5,
2, 3, 4, 6, 8, 12, and 24 hours post-dose, and at 2, 3, 5, 12, 19,
26, 33, and 40 days post-dose. Trough concentrations of
pyronaridine, artesunate, and DHA were assessed on study
Days 1 and 2 before morning dosing.
For all artesunate/DHA and ritonavir samples, 2 mL of
blood was collected in pre-chilled tubes containing fluoride-
oxalate and centrifuged for separation of plasma. Plasma was
transferred into screw cap cryovials and immediately frozen at
or below –80°C until the samples could be shipped to the
Clinical Pharmacokinetics Laboratory at the College of Phar-
macy, the University of Iowa. For pyronaridine samples, 2 mL
of blood was collected in room temperature tubes containing
sodium heparin as an anticoagulant. As with plasma samples,
whole blood samples were frozen at or below –80°C until the
samples could be shipped.
Assay. The liquid chromatography-mass spectrometry
analytical method used for determination of artesunate,
DHA, and ritonavir was developed from an artesunate/DHA
assay described by Naik and others.
6 Briefly, artesunate,
a-dihydroartemisinin, ritonavir, and the internal standard
artemisinin were extracted from 0.25 mL human plasma using
solid phase extraction with Oasis HLB extraction cartridges
(Waters, Milford, MA). Analysis was performed on a
Shimadzu LCMS-2010A (Shimadzu USA, Columbia, MD) in
single ion monitoring positive mode using atmospheric pres-
sure chemical ionization as the interface. Positive ions were
measured using selected ion monitoring mode. Chromatogra-
phy was carried out on a gradient using a PhenomenexSynergi
Max-RP, 4 µ,7 5 +2.0 mm column (Phenomenex, Torrance,
CA) with an initial mobile phase of 0.04% trifluoroacetic
acid, methanol, and acetonitrile (40:45:15) delivered at a
flow rate of 0.25 mL/min. Methanol (0.3 mL/min) was added
post-column to improve ionization and prevent probe nee-
dle clogging. Calibration standards were prepared at concen-
trations ranging from 1 to 1,400 ng/mL for dihydroartemisinin,
2 to 1,400 ng/mL for artesunate, and 4 to 520 ng/mL for
ritonavir. Intraday and interday coefficients of variation were
< 15% for dihydroartemisinin, artesunate, and ritonavir.
The liquid chromatography-mass spectrometry assay used
for pyronaridine was previously described by Naik and
others.
7 Briefly, liquid-liquid extraction with ether was used
for sample preparation, with amodiaquine used as the internal
standard. Analysis was performed on a Shimadzu LCMS-
2010A (Shimadzu) in single ion monitoring mode using
atmospheric pressure chemical ionization as the interface.
Chromatography was performed using a Gemini 5 µm C18
3.0 +150 mm column (Phenomenex) with a 2 mM perfluor-
ooctanoic acid and acetonitrile mixture as a mobile phase
delivered at a flow rate of 0.5 mL/min. The mobile phase was
delivered in gradient mode. Calibration standards were pre-
pared at concentrations ranging from 5.7 to 855 ng/mL.
Pyronaridine intraday and interday coefficients of variation
were both < 15%.
Safety analysis. Vital signs and clinical laboratory parame-
ters (hematological, biochemical, and urinalysis) were obtained
at screening, Day 1 (pre-dose), and at the study completion
visit (Day 50 for Arm A, Day 43 for Arm B) for all subjects.
In Arm A, vital signs (blood pressure and heart rate) were
additionally assessed on Day 8 and Day 17 and clinical labo-
ratory parameters on Days 8 (pre-dose), 11, 15, and 36. In
Arm B, vital signs were additionally assessed on Day 4 and
clinical laboratory parameters on Days 4, 8, and 29. Adverse
effects were assessed at all visits for subjects in both arms.
Twelve-lead electrocardiogram (ECG) tracings were obtained
for subjects in Arm A at screening and at pre-dose, 1.5, 4, and
8 hours post-dose on Day 1 and Day 8. Continuous recording
was conducted on Day 10 from pre-dose through 24 hours
post-dose. The ECG tracings were also obtained on Day 15
and the study completion visit. In Arm B, ECGs were obtained
at screening and at pre-dose, 1.5, 4, and 8 hours post-dose on
Figure 1. Diagram of study drug administration schedule. RIT = ritonavir; PA = pyronaridine/artesunate.
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pre-dose through 24 hours post-dose. The ECG tracings were
also obtained on Day 8 and at the study completion visit. The
ECG tracings and continuous recordings were evaluated in
a central ECG laboratory for changes in morphology, central
tendency in parameters, and outlier effects. The ECGs were
manually read; the QT interval was evaluated after correction
by heart rate by means of both the Bazett (QTcB = QT*[HR/
60]
1/2) and the Fridericia (QTcF = QT*[HR/60]
1/3) correction
where QTc stands for heart rate corrected QT interval, the
final letter indicates the correction used (thus QTcB stands
for QT corrected using the Bazett correction and QTcF stands
for QT corrected using the Fridericia correction) and HR
stands for heart rate.
Genotyping. Genotyping was used to classify each subject
as a CYP2D6 poor, intermediate, or extensive metabolizer.
Pharmacokinetic analysis. The following parameters for
pyronaridine, artesunate, DHA, and ritonavir (as applicable)
were computed by standard noncompartmental methods for
each subject: peak observed concentration (Cmax), time of
peak observed concentration (Tmax), half-life, area under the
concentration-time curve from Hour 0 through the last quan-
tifiable concentration (AUC0-t), area under the concentration-
time curve from 0 to infinity (AUC0-inf), area under the
concentration-time curve from Hour 0 to the scheduled
time of the next dose (AUC0-tau). Half-life was computed as
ln(2)/Kel, where Kel is the magnitude of the slope of the log
concentration versus time profile during the terminal phase.
Kel was only considered estimable if the adjusted R
2 value
for the regression line was equal to at least 0.85 and if a con-
centration decline of at least one-half occurred between the
first and last points used in the regression. For ritonavir, Tmax,
Cmax,C 12h,h a l f - l i f e ,a n dA U C 0-tau were computed for both
Day 1 (0–24 hours post-dose) and Day 10 (0–12 hours post-
morning dose) concentration-time profiles. WinNonlin version 5.0
(Pharsight Corporation, St. Louis, MO) was used to perform
pharmacokinetic analyses.
Values of Cmax, AUC0-tau, AUC0-inf, and AUC0-t were nor-
malized to mg/kg doses of 3.25 mg/kg artesunate for artesunate/
DHA parameters, 9.72 mg/kg pyronaridine tetraphosphate
for pyronaridine parameters, and 1.4 mg/kg ritonavir for rito-
navir parameters to reduce variability in pharmacokinetic
parameters resulting from the differing mg/kg doses adminis-
tered to each subject.
Sample size determination. The sample size for this trial
was calculated for an evaluation of a potential interaction
induced by the coadministration of ritonavir on pyronaridine
pharmacokinetics. In a previous study using the same PA
formulation the highest coefficient of variation for AUC0-inf,
AUC0-t, or Cmax was 35.70%, which was observed for AUC0-t.
The threshold for a clinically relevant difference was set at
33.33% on the basis of prior knowledge of the dose-effect
relationship of pyronaridine. A lack of a relevant interaction
in this study was concluded if the 90% confidence interval
(CI) for the geometric mean of the test (drug administered
with ritonavir)/reference (drug administered without ritonavir)
ratio of parameters lay in the 66.67–150.00% range. For a
coefficient of variation of 35.70% and an equivalence accep-
tance range of 66.67–150.00%, a sample size of 15 subjects per
treatment arm provides a statistical power of 85%. Two addi-
tional subjects per treatment group were recruited to cover
for potential withdrawals.
Statistical analysis. To assess the effects of ritonavir on the
pharmacokinetics of pyronaridine, artesunate, and DHA, the
90% CI for the geometric mean of the test (drug administered
with ritonavir)/reference (drug administered without ritonavir)
ratio for the parameters Cmax,A U C 0-t,A U C 0-inf, and AUC0-tau
were computed using two one-sided t tests. Although the
0.6667–1.5000 interval described previously was used in the
formal drug interaction analysis as the no relevant interaction
interval for pyronaridine, artesunate, and DHA, this interval
was considered to be most clinically relevant to an interaction
effect on pyronaridine pharmacokinetics. Given the broad
artesunate dosage range recommended by the World Health
Organization (WHO) for treatment of acute uncomplicated
malaria (2–10 mg/kg/day),
8 and the lack of artesunate dosing
above 5 mg/kg/day in the recommended PA dosing scheme,
a clinically relevant increase in artesunate/DHA exposure
would necessitate a drug interaction effect of substantially
greater magnitude than the 33.33% difference delimiting the
0.6667–1.5000 interval. However, a decrease in artesunate/DHA
exposure of only slightly > 33.33% could certainly be clini-
cally relevant, particularly for subjects receiving < 3m g / k g / d a y
of artesunate.
The effects of PA on the pharmacokinetics of ritonavir were
assessed by constructing a 90% CI, based on a paired sample
t test, for the geometric mean ratio between the AUC0-12hr
on Day 10 (during administrationofritonavirwithPA)andthe
AUC0-inf on Day 1. In the absence of any interaction or time-
dependent effect on ritonavir pharmacokinetics, this ratio
would be expected to equal 1. The software SPSS 17 (SPSS,
Inc.,Chicago,IL)wasusedtoperformstatisticalanalyses.
RESULTS
Subject demographics. Thirty-four subjects were enrolled
in the trial and randomized equally to Arm A and Arm B. In
Arm A, 9 of 17 subjects were male; in Arm B, 11 of 17 sub-
jects were male. One subject in Arm B was withdrawn from
the study because of vomiting after the first dose of PA; this
subject was not included in pharmacokinetic analyses. Four
subjects were withdrawn from Arm A because of liver enzyme
elevations detected during ritonavir and PA coadministration
as detailed under “Safety analysis” below.
In Arm A, three subjects were classified as poor CYP2D6
metabolizers, eight as intermediate CYP2D6 metabolizers,
and six as extensive CYP2D6 metabolizers. In Arm B, one
subject was classified as a poor CYP2D6 metabolizer, six as
intermediate CYP2D6 metabolizers, and nine as extensive
CYP2D6 metabolizers.
Safety analysis. No clinically significant changes in the
hematologic or urinalysis laboratory parameters were observed
during the course of the study. Additionally, no trends were
detected in mean or individual subject supine systolic and
diastolic blood pressure and pulse rate or in their orthostatic
changes upon standing. Although transient changes in blood
pressure and pulse rate were noted at isolated time points
for some subjects, none of these findings were judged clini-
cally important.
Adverse events occurring in more than two subjects are
summarized in Table 1. Diarrhea was the most commonly
reported drug-related adverse event after PA administered
alone. The incidence of diarrhea was similar in subjects
who received PA alone (9 events in 8 of 17 subjects) or in
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number of drug-related adverse events reported after ritona-
vir alone was low, with headache and fatigue being the only
two adverse events reported on more than one occasion.
Clinically significant findings in biochemical laboratory
parameters were observed only for liver function parameters.
Elevations in aminotransferases deemed clinically significant
by study physicians, with peak values above 3.0 +upper limit
of normal (ULN), were observed in five subjects, four females
and one male, after ritonavir and PA coadministration. Four
of these subjects were withdrawn from the study because of
these elevations. Among the four subjects withdrawn from the
study, the elevations were more than 5 +ULN for both ALT
and AST; AST was observed for two subjects and for ALT
only for one subject. None of the elevations in liver amino-
transferases fulfilled Hy’s law criteria for drug-induced liver
injury as defined in the U.S. Food and Drug Administration
(FDA) Guidance on the Premarketing Evaluation of Drug-
induced Liver Injury,
9 because all values of serum bilirubin
determined during the treatment period remained within the
normal range. Additionally, no decreases in serum albumin or
increases in international normalized ratio, creatine kinase, or
lactate dehydrogenase were observed in these subjects. None
of these subjects had increased blood eosinophil counts at
any time. The four subjects withdrawn from the study were
screened for a panel including the most frequent viruses (cyto-
megalovirus DNA and immunoglobulin M [IgM], Epstein-
Barr, hepatitis A, B, and E IgM, hepatitis C RNA) responsible
for viral hepatitis, with negative results in all cases.
The clinically significant ALT increases were first noticed
on Day 8 in one subject, Day 11 in three subjects, and Day 15
in a fifth subject. The ALT had returned to the reference
range by Days 22, 29, 43, and 50 in one subject each. Values
were still high but decreasing by Day 17 (ALT 3.0 +ULN
down from a peak on Day 13 of 9.8 +ULN) in one subject
in whom no further follow-up within the study is available;
additionally, by the time this subject left the study, AST
had returned to the reference range from a peak on Day 11
of 5.4 +ULN.
Some of the subjects with clinically significant increases
in ALT reported potentially associated symptoms concomi-
tantly with the ALT increase, including two cases of fatigue,
two cases of nausea, and one case of decreased appetite.
Abdominal pain was also reported by two subjects, but in
one of the subjects it was initially reported before the ALT
increase and was associated with diarrhea.
Lower grade increases in ALT (values below 3 +ULN)
were observed in some additional subjects on PA coadmin-
istered with ritonavir (up to 6 of 17 total subjects with
increased ALT and up to 7 of 17 subjects with increased AST
on a given day) and in up to 4 of 16 subjects treated with PA
alone. The maximum number of subjects on PA alone with
aminotransferase increases was found on Days 4 and 8 for
ALT and on Day 8 for AST.
The relative increase in mean ALT (Arm A: ratio of Day 15
value [peak]/Day 1 value was 4.4; Arm B: ratio of Day 8 value
[peak]/Day 1 value was 2.2) was higher than the relative
increase in mean AST (Arm A: ratio of Day 11 value [peak]/
Day 1 value was 2.6; Arm B: ratio of Day 4 value [peak]/Day 1
value was 1.5). No subjects had clinically relevant increases in
AST but not in ALT. Increases in ALP were less frequent
than those in ALT and AST (up to three subjects receiving
ritonavir/PA on Day 15, with these three subjects also having
clinically significant increases in ALT, and only one subject
receiving PA alone). The influence of CYP2D6 genotype
could not be definitively evaluated because of the small
number of subjects from each CYP2D6 metabolizer class.
Few changes in ECG morphology were noted during this
study. None of the observed findings was considered to be a
relevant abnormality of the ventricular rhythm Heart rate
corrected QT interval values and did not exhibit any increas-
ing trend after PA administration. Few subjects (QTcB 2 of
17 on ritonavir alone, 1 of 17 on PA + ritonavir and 1 of 17 on
PA alone; QTcF 1 of 17 on PA alone) had corrected QT
values that exceeded 450 ms and none of the subjects had a
value that exceeded 500 ms or a change from baseline in
corrected QT exceeding 60 ms.
Pharmacokinetic analysis. The geometric mean half-life of
pyronaridine was 14.2 and 13.1 days for Arm A and Arm B,
respectively, with peak concentrations occurring on average
at 1.8 hours in Arm A and 1.4 hours in Arm B. Further details
of the pyronaridine parameters are given in Table 2. The
90% CI for the ratios of geometric means of most pharmaco-
kinetic parameters were contained in the 0.6667–1.500 range,
as shown in Table 3. The only exception was Cmax, for which
the upper limit of the 90% CI (point estimate 1.2255 with
a 90% CI: 0.9983, 1.5045) extended slightly above the pre-
defined no relevant effect interval. No association was
apparent between CYP2D6 genotype and any pyronaridine
pharmacokinetic parameter (data not shown).
The average half-life of artesunate was 0.410 hours and
0.433 hours in Arm A and Arm B, respectively. The AUC0-inf
Table 1
Treatment emergent adverse events occurring in more than two
subjects for any of the treatments (all causalities)
Number of subjects with adverse events
Arm A (N = 17) Arm B (N = 17)
Ritonavir Ritonavir + PA PA
Abdominal pain upper 1 3 2
Diarrhea 1 7 8
Nausea 3 3
Fatigue 2 2 1
ALT increased > 3 +ULN 5
Dizziness 1 2 4
Headache 2 4 5
Hot flush 3
PA = pyronaridine/artesunate; ALT = alanine aminotransferase; ULN = upper limit
of normal.
Table 2
Pharmacokinetic parameters of pyronaridine in subjects administered
pyronaridine/artesunate (PA) + ritonavir (Arm A) or administered
PAonly.Cmaxandareaunderthecurve(AUC)valuesarenormalized
to 9.72 mg/kg†
Arm A (PA + ritonavir)
[N = 17]
Arm B (PA only)
[N = 16]
Half-life (days) 14.2 (50.3%)‡ 13.1 (20.5%)
Tmax (days) 0.078 (65.5%) 0.059 (25.7%)
Cmax (ng/mL) 462.0 (28.5%) 377.2 (42.6%)
Ctrough (ng/mL) 119.2 (47.5%) 114.1 (36.8%)
AUC0-t (day*ng/mL) 955 (38.0%)§ 1059 (34.7%)
AUC0-inf (day*ng/mL) 1212 (24.3%)‡ 1248 (34.4%)
AUC0-tau (day*ng/mL) 222 (36.5%) 210 (36.8%)
†All values given as geometric mean (geometric %CV).
‡N = 15.
§N = 16.
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be expected given the observed rapid elimination of artesunate
(Table 4). The 90% CIs for the Arm A/Arm B ratio of geo-
metric means of Cmax, AUC0-t, AUC0-inf, and AUC0-tau are
given in Table 3; these CIs were not wholly contained within
the 0.6667–1.500 range, largely because of the high between
subject variability associated with the artesunate pharmaco-
kinetic parameters. Considering point estimates for ratios of
these parameters, coadministration of ritonavir appeared to
result in a negligible effect on Cmax and mean increases of up
to 27% in the AUC values of artesunate.
The DHA pharmacokinetic parameters in the two study
arms are presented in Table 4, with the 90% CIs for the ratios
of geometric means of Cmax, AUC0-t, AUC0-inf, and AUC0-tau
given in Table 3. The lower limit of the 90% CIs for the Arm A/
Arm B ratios of all of these parameters extend below 0.6667,
with the upper limit of the CIs falling at 0.9815 for Cmax and
below 0.85 for all AUC parameters. The point estimates for the
ratios of geometric means indicate that on average, ritonavir
coadministration was associated with decreases in DHA Cmax,
AUC0-t, and AUC0-inf of ~27%, 36%, and 38%, respectively.
Pharmacokinetic parameters for ritonavir are shown in
Table 5. The average ritonavir half-life estimates on Day 1
and Day 10 were 6.46 and 3.96 hours, respectively. For all
subjects this half-life decrease remained essentially constant
from Day 1 to Day 10. The point estimate and 90% CI of the
ratio of geometric means for AUC0-12hr on Day10 (steady
state) and AUC0-inf on Day 1 was computed to be 3.2001
(90% CI: 2.5678, 3.9882). In the absence of any time-dependent
or interaction-dependent changes in ritonavir pharmaco-
kinetics, the accumulation ratio should have resulted in a
value of 1.0 rather than 3.2.
Pharmacokinetic/safety correlation. Analysis of artesunate,
DHA, ritonavir, and pyronaridine pharmacokinetic parame-
ters (unadjusted for mg/kg dosing to reflect individual patient
exposure) in subjects with clinically significant hepatic enzyme
elevations yielded no clear pattern for artesunate, DHA, or
ritonavir parameters. However, within Arm A these subjects
displayed four of the top five pyronaridine Cmax values, with
these four values corresponding to the first, second, fourth,
and seventh highest Cmax values in the combined Arm A and
Arm B population. The three highest AUC0-tau values in Arm A
were observed in the three Arm A subjects displaying ALT
elevations more than 5 +ULN. These three values corre-
sponded to the first, third, and fourth highest AUC0-tau values
in the combined population. Overall, despite the trend toward
higher pyronaridine Cmax and AUC0-tau values among sub-
jects experiencing clinically significant aminotransferase
elevations, there was notable overlap in the magnitude of
parameters in subjects displaying and those not displaying
significant liver enzyme elevations.
DISCUSSION
The objective of this study was to determine whether there
was a drug interaction with pharmacokinetic or safety impli-
cations between ritonavir, administered at doses used for
pharmacokinetic boosting, and fixed dose PA in healthy sub-
jects. On the basis of the 90% CI for the ratio of geometric
means of Cmax, there was an effect, on average, of ritonavir
on pyronaridine pharmacokinetics. However, these findings
appear to lack clinical relevance as the 90% CI was very close
to the acceptance range. For artesunate, the high degree of
variability among the subjects in Cmax and AUC values
resulted in wide CIs for the ratios of those values between
the two study groups. On average, although Cmax values were
similar in the presence and absence of ritonavir, artesunate
Table 3
Geometric mean ratios (90% confidence intervals [CI]) for the pharmacokinetic parameters of pyronaridine, artesunate, and DHA after
administration with ritonavir (Arm A) or without ritonavir (Arm B)
Ratio: Arm A/Arm B (90% CI)
Pyronaridine [N = 33] Artesunate [N = 33] DHA [N = 33]
Cmax 1.2255 (0.9983, 1.5045) 0.9954 (0.6408, 1.5462) 0.7348 (0.5500, 0.9815)
AUC0-t 0.9020 (0.7277, 1.1181)* 1.1470 (0.7833, 1.6797) 0.6432 (0.4875, 0.8486)
AUC0-inf 0.9717 (0.8132, 1.1610)† 1.2707 (0.8481, 1.9038)‡ 0.6169 (0.4562, 0.8343)¶
AUC0-tau 1.0590 (0.8589, 1.3058) 1.2691 (0.8476, 1.9001‡ 0.6170 (0.4565, 0.8338)¶
*N = 32.
†N = 31.
‡N = 21.
¶N = 30.
AUC = area under the curve.
Table 4
Pharmacokinetic parameters of artesunate and dihydroartemisinin (DHA) in subjects administered pyronaridine/artesunate (PA) + ritonavir
(Arm A) or administered PA only*
Artesunate DHA
Arm A (PA + ritonavir) [N = 17] Arm B (PA only) [N = 16] Arm A (PA + ritonavir) [N = 17] Arm B (PA only) [N = 16]
Half-life (hours) 0.410 (28.0%)† 0.433 (39.5%)‡ 2.04 (52.6%)¶ 2.18 (42.4%)§
Tmax (hours) 1.05 (61.4%) 0.75 (54.2%) 1.77 (40.5%) 1.39 (29.1%)
Cmax (ng/mL) 95.1 (108%) 95.5 (61.9%) 539.5 (63.9%) 734.3 (37.6%)
AUC0-t (hours*ng/mL) 120 (86%) 105 (55.5%) 1151 (61.2%) 1790 (35.1%)
AUC0-inf (hours*ng/mL) 157 (70.5%)† 124 (49.3%)‡ 1164 (63.9%)¶ 1887 (34.4%)§
AUC0-tau (hours*ng/mL) 157 (70.5%)† 124 (49.1%)‡ 1162 (63.8%)¶ 1884 (34.2%)§
*Cmax and area under the curve (AUC) values are normalized to an artesunate dose of 3.25 mg/kg. All values given as geometric mean (geometric %CV).
†N =9 .
‡N = 13.
¶N = 16.
§N = 14.
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artesunate is hydrolyzed through esterase activity,
10 no clear
mechanism for an interaction between artesunate and rito-
navir is apparent. Any interaction effect ritonavir may be
exerting on artesunate pharmacokinetics is likely minor in
relation to the extreme underlying between subject vari-
ability in artesunate pharmacokinetics.
More definitive interaction effects were apparent for DHA,
with both peak concentrations and exposure to DHA being
lower in the setting of ritonavir coadministration. The DHA
is eliminated through conjugation with glucuronic acid by
UGTs.
5 Induction of the metabolizing UGTs by ritonavir
could certainly account for the lower DHA AUC values
detected in subjects receiving ritonavir. Additionally, the
observed reduction in DHA AUC is consistent with reduc-
tions in DHA exposure observed when artemether/lumefantrine
was coadministered with lopinavir/ritonavir (400 mg/100 mg
bid).
11 Artemether/lumefantrine coadministration was car-
ried out at the end of the second week of lopinavir/ritonavir
administration. Coadministration with lopinavir/ritonavir
resulted in DHA Cmax and AUC0-t reductions of 36% and
45%, respectively. There was a trend toward decreases in
these measures for artemether, the parent drug, as well; how-
ever, because these decreases were smaller than those found
for DHA, ritonavir induction of DHA metabolism likely
contributed to the observed reductions in DHA exposure.
Coadministration of PA resulted in substantially increased
exposure to ritonavir, suggesting that either total body clear-
ance decreased and/or the extent of ritonavir absorption
increased. From in vitro evidence, pyronaridine is an inhibitor
of CYP2D6, which is involved in the metabolism of ritonavir,
and of P-gp, which is involved in the efflux transport of rito-
navir.
1,3,12,13 Either CYP2D6 or P-gp inhibition could produce
the observed increase in exposure. If the increase in exposure
stemmed primarily from CYP2D6 inhibition, some increase in
ritonavir half-life on Day 10, as compared with Day 1, would
be anticipated. However, half-life decreased or remained
essentially constant, suggesting that the increased ritonavir
exposure may have stemmed primarily from pyronaridine
inhibition of P-gp mediated ritonavir efflux. It should be
noted that the design of this study does not allow for effects
of PA on ritonavir pharmacokinetics to be differentiated from
any intrinsic time-dependency of ritonavir pharmacokinetics.
Hsu and others
14 evaluated time-dependent ritonavir phar-
macokinetics and determined that pre-dose concentrations
trended downward when examined from Day 5 to Day 16
of ritonavir administration; the authors propose ritonavir
auto-induction as the source of the decline in pre-dose con-
centrations. In this study, ritonavir auto-induction would
be expected to decrease Day 10 AUC0-tau relative to Day 1
AUC0-inf. Because a marked increase was observed
instead, it is highly likely that drug interaction effects, rather
than time-dependent changes in ritonavir pharmacokinetics,
are responsible.
The PA administered alone for 3 days was well tolerated,
with gastrointestinal adverse effects being most commonly
reported. Following PA coadministration with ritonavir, a
similar pattern of adverse events was observed with the
exception of clinically significant, but reversible, increases in
ALT, with or without increases in AST occurring in five sub-
jects. These increases returned to baseline during Days 22
to 50 in four of the subjects, whereas in the fifth it was
decreasing by Day 17 (ALT 3.0 +ULN on Day 17 down from
a peak of 9.8 +ULN on Day 13 and with three values in
between decreasing as compared with the previous one).
Although there was a trend toward higher pyronaridine Cmax
and AUC0-tau levels in these five subjects, there was over-
lap between these parameters in subjects displaying and
not displaying liver enzyme elevations. This was particu-
larly true when considering the combined Arm A and
Arm B population.
The PA therapy administered alone to healthy subjects has
previously resulted in liver enzyme elevations, but the inci-
dence and severity of the elevations observed in Arm A of the
present trial would not be anticipated based upon previous
PA trials.
15,16 Ritonavir itself has been associated with hepatic
enzyme elevations in clinical trials.
1 However, ritonavir expo-
sure alone cannot account for elevations observed in this trial.
In particular, despite the elevated Day 10 ritonavir concentra-
tions, ritonavir exposure in this trial would still remain below
exposure resulting from the 600 mg twice daily ritonavir
regimen used for antiretroviral therapy in many ritonavir
clinical trials.
1 Additionally, such trials typically involved
HIV-positive patients who, unlike the healthy volunteers in
our study, could present with comorbidities and receive
comedications predisposing them to ALT and AST eleva-
tions. Therefore, PA and ritonavir exposure considered
separately cannot account for the observed liver enzyme ele-
vations in this trial. Instead, coadministration of ritonavir and
PA appear to have increased the likelihood of liver enzyme
elevations in a manner that cannot be accounted for by the
observed pharmacokinetic parameters from any one of the
examined moieties.
Although this study did not allow for the precise mecha-
nism of the hepatic enzyme elevations associated with PA and
ritonavir coadministration to be elucidated, two definitive
pharmacokinetic conclusions can be drawn from this trial.
First, PA coadministration appears to substantially increase
ritonavir exposure, likely caused by pyronaridine P-gp inhibi-
tion of ritonavir efflux. Second, ritonavir coadministration
substantially decreases exposure to DHA. This finding is of
particular clinical relevance because currently available ACTs
contain artesunate or artemether, which are metabolized to
DHA, or DHA itself. The reduced exposure to DHA associ-
ated with ritonavir coadministration poses an increased risk of
suboptimal antimalarial efficacy; the clinical effects of reduced
exposure may be augmented by the immunocompromised
state of the patient population receiving ritonavir therapy.
Given this risk, the pharmacokinetic and clinical effects of
ritonavir coadministration on DHA pharmacokinetics are
deserving of further investigation, optimally in an HIV-positive
patient population, to determine if dose adjustments of
Table 5
Pharmacokinetic parameters of ritonavir from Day 1 and Day 10*
Day 1 [N = 17] Day 10 [N = 17]
Half-life (hours) 6.46 (27.3%) 3.96 (25.1%)
Tmax (hours) 3.46 (51.6%) 2.27 (39.5%)
Cmax (ng/mL) 492 (81.1%) 2751 (52.4%)
C12hr (ng/mL) 147.7 (59.3%) 416 (57.7%)
AUC0-12hr (hours*ng/mL) 3072 (73.8%) 14825 (51.8%)
AUC0-inf (hours*ng/mL) 4633 (62.4%)
AUC0-24hr (hours*ng/mL) 4127 (65.2%)
*Cmax and area under the curve (AUC) values are adjusted for 1.4 mg/kg q12hr dose. All
values given as geometric mean (geometric %CV).
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